Windlas Biotech Ltd reported record Q4 and FY25 financial results, achieving ₹760 Cr in revenue for FY25 and ₹203 Cr for Q4, with a YoY growth of 20% and 18% respectively. EBITDA stood at ₹94 Cr for FY25 and ₹26 Cr for Q4, reflecting a significant performance amidst ongoing capacity expansions.